Abstract

The application of mesh-reinforced hiatal closure has resulted in a significant reduction in recurrence rates in comparison with primary suture repair. However, the use of meshes has not completely extended in all the cases of large paraesophageal hiatal hernias (LPHH) due to the complications related to them. The aim of this study is to present our long-term results and complications related to Crurasoft® mesh (Bard) for the treatment of LPHH. From January 2004 to December 2014, 536 consecutive patients underwent open or laparoscopic fundoplication for gastroesophageal reflux disease or LPHH at Ramón y Cajal University Hospital. Primary simple suture of the crura and additional reinforcement with a Crurasoft® mesh (Bard) was performed in 93 patients (17.35%). Radiologic hiatal hernia recurrence and mesh-related complications were investigated. Of the 93 patients undergoing mesh repair, there were 28 male and 65 female with a mean age of 67.27years (range 22-87years). Laparoscopic surgery was attended in 88.2% of the cases, and open surgery in the rest 11.8%. Mean operative time was 167.05min (range 90-370min). Median postoperative stay was 4.79days (range 1-41days). Conversion rate was 8.53% (7 patients). Intraoperative complications were described in 10.75% (10 patients), but all of them, except in one case, could be managed laparoscopically. Overall postoperative complications rate was 28%. Early postoperative complications occurred in 11 patients (12%), respectively, for grades 2 (6 cases), 3b (1 case) and 5 (4 cases) according to the Clavien-Dindo classification. Late postoperative complications occurred in 15 patients (16%), respectively, for grades 1 (7 cases), 2 (2 cases), 3b (5 cases) and 5 (1 case) according to the Clavien-Dindo classification. Thirty day-mortality rate was 4.3%. Mortality rate specific associated with the mesh was 1%. Reoperation rate was 5.4%. After a median follow-up of 76.33months (range 3-130months), 8 patients (9%) developed a recurrent hiatal hernia. Mesh was removed in three cases (3.22%). In our experience, the recurrence rate in patients with a Crurasoft® (Bard) is acceptable. However, the rate of postoperative complications and mortality is excessive. The use of meshes in the hiatus keeps on being controversial due to the severe complications related to them. It would be advisable to compare our results in the non-mesh group in terms of recurrences and complications, to determine if meshes in the hiatus should be given in these patients due to its high rate of complications.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.